Other news

u-card-img-1
News
Publication in Molecular Cell

A magic alarmone to rescue hungry bacteria

Abel Garcia-Pino (WELBIO – ULB) and his team shed light on the role played by  alarmone for induction of the synthetic activity of E. coli RelA by starved ribosomes.

Learn more
u-card-img-1
News
Publication in Molecular Cell

An old fold can learn new tricks

Abel Garcia-Pino (WELBIO – ULB) and his team uncovered the mechanism of toxicity used by the toxin-antitoxin systems (toxSAS) in bacteria.

Learn more
u-card-img-1
News

2020 Annual report

2020 marks the 10th anniversary of our first call for projects! Learn about our researchers, their scientific advances and how some of their discoveries have been translated into applications for human health.

Learn more
u-card-img-1
News
Publication in Nature Cancer

RNA epigenetics as a key regulator of cancer metastasis

François Fuks (WELBIO – ULB) and his team demonstrated the role of the regulation of RNA epigenetics by the FTO enzyme in the development of cancer metastasis.

Learn more
u-card-img-1
News
Spin-off creation

NeuVasQ: An innovative approach to fight against neurovascular and neurodegenerative diseases

From disruptive research of scientific founder Benoit Vanhollebeke (WELBIO - ULB) to the development of blood-brain barrier pharmaceuticals aiming at repairing neurovascular function and neurodegenerative diseases.

Learn more
u-card-img-1
News
Publication in Gut

D. welbionis : potential implications for metabolic diseases

A new bacterium, made in Belgium

Patrice Cani (WELBIO - UCLouvain) describes the properties displayed by D. welbionis, a new bacterium present in 70% of the population, that open the doors for potential treatment for type 2 diabetes, obesity and inflammatory diseases.

Learn more
u-card-img-1
News
Publication in Nature Communications

Wobble transfer RNA modifications optimize dynamic proteome expression

Pierre Close (WELBIO – ULiège) and Francesca Rapino describe how the regulation of transfer RNAs and modification of their anticodon impact the dynamics of protein synthesis and regulate protein folding and stability.

Learn more
u-card-img-1
News
Publication dans Science Advances

Maladies auto-immunes, des signatures moléculaire similaires au niveau des tissus cibles ?

L'utilisation d'inhibiteurs de TYK2 - déjà utilisés pour d'autres maladies auto-immunes - protège les cellules β contre les dommages induits par le système immunitaire

Decio Eizirik (WELBIO - ULB) et son équipe décrivent des signatures moléculaires similaires entre différentes maladies auto-immunes, identifiant des voies clés qui pourraient être ciblées pour la thérapie.

Learn more
u-card-img-1
News
Publication in Nature

Cancer: Tumor driver promoting EMT, metastasis and resistance to therapy

New therapy for FAT1 mutated cancers

Cédric Blanpain (WELBIO – ULB) and his team identify the functions of FAT1, one of the most frequently mutated cancer gene drivers, uncovering that FAT1 mutations promote invasive features, metastasis and resistance to commonly used anti-cancer drugs

Learn more
u-card-img-1
News
The "Belgian Nobel Prize"

The Francqui-Collen Prize 2020 is awarded to Cédric Blanpain

Prize awarded to a Belgian investigator less than 50 y.o. “who has made an important contribution to science augmenting the prestige of Belgium".”

Director of the Laboratory of Stem Cells and Cancer (ULB), WELBIO investigator, Pr. Cédric Blanpain is awarded the Francqui-Collen Prize for his fundamental research in cancer and stem cells biology.

Learn more
u-card-img-1
News
Important collaboration agreement with Kaneka Eurogentec

From fundamental research on bacterial stress to the production of biomedicines.

The use of biomedicines is disrupting current medicine

Kaneka and its Walloon subsidiary, Kaneka Eurogentec S.A., enter into a partnership with Jean-François Collet's laboratory (WELBIO - UCLouvain) by funding a new joint research group at the Duve Institute.

Learn more
u-card-img-1
News
Déclarez-vous volontaire !

Luttons tous ensemble contre le Covid-19

Boostons la recherche clinique

WELBIO lance aujourd’hui une plateforme digitale permettant aux citoyens de se déclarer volontaires pour des études cliniques relatives au Covid-19 : https://rechercheclinique.be/

Learn more

Share this page